Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23648339 | 0.87 | GRIA2 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL3600451 | 0.81 | MAOA (0.31) | — | |
| SCHEMBL31359566 | 0.79 | NLRP3 (0.38) | — | |
| SCHEMBL3604621 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL17659028 | 0.76 | MEN1 (0.35) | — | |
| SCHEMBL24819190 | 0.72 | KDM4E (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL23012562 | 0.72 | MAPT (0.35) | — | |
| SCHEMBL21603512 | 0.72 | MAOA (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL15667176 | 0.71 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL23648258 | 0.71 | CA1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-09-15 | — | — | US | disclosed |
| EP-4013761-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114401971-A | Macrocyclic sulfonylurea derivatives as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | HTR2A 3922/4885HTR2C 4026/4885HTR2B 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.